All articles tagged with #arrowhead pharmaceuticals
Sarepta Therapeutics sold its entire stake in Arrowhead Pharmaceuticals to improve its cash position amid challenges with its gene therapy product, Elevidys, leading to a significant drop in Arrowhead's stock price and raising concerns about Sarepta's financial outlook and future drug development prospects.
In Jim Cramer's Lightning Round, he advises buying shares of Norfolk Southern in stages due to its attractive valuation, expresses optimism about Sofi's stock potential, warns investors to stay away from VinFast as it is not a company worth getting involved with, recommends buying shares of PG&E, and refrains from recommending stocks that are losing money like Arrowhead Pharmaceuticals. Cramer also praises Accenture for its strong leadership and expertise in technology solutions.